Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Anaconda Biomed is a medical device start-up that develops the next generation of catheters to perform efficient mechanical thrombectomies.
DescriptionIFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.
Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.
First Wave Bio develops medical solutions to address the lack of effective and safe treatments for Inflammatory Bowel Disease (IBD).
Clinical development and commercialization of innovative aesthetics and medical dermatology products based on scientific breakthroughs
BioSilta Ltd, a developer of advanced microbial growth systems,
Omega Funds has invested in 80 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Omega Funds's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Biopharma. The firm invests across 12 different industry categories.
Among tracked funding rounds, Translate Bio received $125.0M in a Post Ipo Equity round. Omega Funds's total known invested capital is $5.7B.
Omega Funds's average investment size is $97.0M across its portfolio of 80 companies.
Recent Omega Funds portfolio additions include Translate Bio. These companies were founded in 2020 or later.